Sam Lipman supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

He applies his background in drug development and market research to a broad range of client projects.

Prior to joining Avalere, Sam was a business analyst at InMed Pharmaceuticals, where he conducted research on rare skin diseases. Previously, as a business development intern at Fortress Biotech, Sam performed financial modeling on potential acquisitions and analyzed financial statements of pharmaceutical securities.

Sam has an MS in neuroscience and a BS in neuroscience and political science from Tulane University.

Authored Content

The FDA has adjusted its priorities in response to the COVID-19 pandemic and the agency is expediting decisions on testing, therapies, and vaccines on a daily basis.

In response to the COVID-19 pandemic, FDA has announced actions that may have much broader implications for drug development, lifecycle management, and oversight.

A new FDA resource is available to identify drug candidates for additional study and serve as a resource to shape medical decisions.